|
article-title
|
Loss of Function of the Nuclear Receptor NR2F2, Encoding COUP-TF2, Causes Testis Development and Cardiac Defects in 46,XX Children
|
|
abstract
|
Emerging evidence from murine studies suggests that mammalian sex determination is the outcome of an imbalance between mutually antagonistic male and female regulatory networks that canalize development down one pathway while actively repressing the other. However, in contrast to testis formation, the gene regulatory pathways governing mammalian ovary development have remained elusive. We performed exome or Sanger sequencing on 79 46,XX SRY-negative individuals with either unexplained virilization or with testicular/ovotesticular disorders/differences of sex development (TDSD/OTDSD). We identified heterozygous frameshift mutations in NR2F2, encoding COUP-TF2, in three children. One carried a c.103_109delGGCGCCC (p.Gly35Argfs∗75) mutation, while two others carried a c.97_103delCCGCCCG (p.Pro33Alafs∗77) mutation. In two of three children the mutation was de novo. All three children presented with congenital heart disease (CHD), one child with congenital diaphragmatic hernia (CDH), and two children with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). The three children had androgen production, virilization of external genitalia, and biochemical or histological evidence of testicular tissue. We demonstrate a highly significant association between the NR2F2 loss-of-function mutations and this syndromic form of DSD (p = 2.44 × 10−8). We show that COUP-TF2 is highly abundant in a FOXL2-negative stromal cell population of the fetal human ovary. In contrast to the mouse, these data establish COUP-TF2 as a human “pro-ovary” and “anti-testis” sex-determining factor in female gonads. Furthermore, the data presented here provide additional evidence of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have divergent functions in mouse and human biology.
|
|
p
|
Emerging evidence from murine studies suggests that mammalian sex determination is the outcome of an imbalance between mutually antagonistic male and female regulatory networks that canalize development down one pathway while actively repressing the other. However, in contrast to testis formation, the gene regulatory pathways governing mammalian ovary development have remained elusive. We performed exome or Sanger sequencing on 79 46,XX SRY-negative individuals with either unexplained virilization or with testicular/ovotesticular disorders/differences of sex development (TDSD/OTDSD). We identified heterozygous frameshift mutations in NR2F2, encoding COUP-TF2, in three children. One carried a c.103_109delGGCGCCC (p.Gly35Argfs∗75) mutation, while two others carried a c.97_103delCCGCCCG (p.Pro33Alafs∗77) mutation. In two of three children the mutation was de novo. All three children presented with congenital heart disease (CHD), one child with congenital diaphragmatic hernia (CDH), and two children with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). The three children had androgen production, virilization of external genitalia, and biochemical or histological evidence of testicular tissue. We demonstrate a highly significant association between the NR2F2 loss-of-function mutations and this syndromic form of DSD (p = 2.44 × 10−8). We show that COUP-TF2 is highly abundant in a FOXL2-negative stromal cell population of the fetal human ovary. In contrast to the mouse, these data establish COUP-TF2 as a human “pro-ovary” and “anti-testis” sex-determining factor in female gonads. Furthermore, the data presented here provide additional evidence of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have divergent functions in mouse and human biology.
|
|
body
|
Main Text
The sex chromosomes of an individual usually direct gonadal sex development toward either a testis or ovary pathway. In 46,XY individuals, the presence of the Y chromosome testis-determining gene SRY (MIM: 601947) triggers a genetic cascade that both initiates testis formation and represses the formation of the ovary.1 Although many factors are known to be involved in early testis development, far less is known about genetic factors controlling the ovary.1 However, emerging evidence suggests that ovary development involves more than just a default (passive) pathway,2 consistent with the Z-factor theory proposed 25 years ago that the XX gonad expresses an elusive factor that actively promotes both “anti-testis” and “pro-ovary” functions.3
The genomic analysis of 46,XX individuals with testes (sometimes known as testicular disorders/differences of sex development [TDSD]; [MIM: 400045]) or ovotestes (ovotesticular DSD [OTDSD]) supports the hypothesis that “pro-testis/anti-ovary” or “pro-ovary/anti-testis” genetic pathways exist.4, 5, 6 These children typically present with virilized genitalia due to testosterone production from the presence of testicular tissue. Many individuals with TDSD and a minority with OTDSD have a translocation of the testis-determining SRY gene, usually onto one of the X chromosomes, whereas a small proportion have chromosomal rearrangements associated with upregulation (gain-of-function) of SOX gene expression (e.g., duplications of the RevSex [MIM: 616425] enhancer of SOX9 [MIM: 608160] and rearrangements of the SOX3 locus [MIM: 800833]).5, 6 This ectopic SOX gene expression increases “pro-testis” factors in the early developing ovary and results in a reprogramming of cellular sex identity to testis-typical Sertoli cells. Other rare forms of 46,XX DSD can occur due to mutations (loss-of-function) involving genes that are “pro-ovary/anti-testis.” The best example of this is in the WNT4/RSPO1 signaling pathway, which stabilizes β-catenin and is required for ovary development.7 Very rare heterozygous or homozygous mutations in WNT4 (MIM: 603490) cause Müllerian aplasia/hyperandrogenism (MIM: 158330)8 or testis development (SERKAL syndrome [MIM: 611812]) in 46,XX individuals, respectively, whereas homozygous RSPO1 (MIM: 609595) mutations are also associated with testis formation and skin phenotypes in 46,XX children (MIM: 610644).7 FOXL2 (MIM: 605597) is a forkhead/winged helix transcription factor, which is also a potential “pro-ovary” and “anti-testis” gene. Goat XX fetuses lacking Foxl2 have gonads resembling testes and the induced absence of Foxl2 in adult XX mice results in trans-differentiation of the ovaries into a testis-like gonad.9, 10, 11 In humans, heterozygous loss-of-function FOXL2 mutations are associated with autosomal-dominant blepharophimosis-ptosis-epicanthus inversus syndrome (BPES [MIM: 110100]) either with (type I) or without (type 2) ovarian insufficiency as well as ovarian insufficiency without BPES (MIM: 608996), but homozygous FOXL2 disruption has not been described.10 The limited understanding of the genes involved in ovary formation means that for most children with OTDSD/TDSD, the molecular basis is currently unknown.
Here, we report the molecular etiology of a syndromic form of 46,XX DSD that includes genital virilization, congenital heart disease (CHD), and variable somatic anomalies including BPES and congenital diaphragmatic hernia (CDH). This syndrome is caused by protein-truncating mutations in the orphan nuclear receptor NR2F2 (MIM: 107773). NR2F2 encodes the transcription factor chicken ovalbumin upstream promoter transcription factor 2 (COUP-TF2).12 Our data indicate that in the early developing human chromosomal female XX gonad, COUP-TF2 is a human “pro-ovary” and “anti-testis” sex-determining factor.
Following written informed consent and with local ethics committee approvals, whole-exome sequencing was performed on 69 46,XX individuals with either unexplained virilization (n = 14) or unexplained OTDSD/TDSD (n = 55) as described elsewhere.13 Sanger sequencing of NR2F2 was performed on DNA from a further 10 individuals with 46,XX OTDSD/TDSD where there was insufficient DNA for complete exome analysis. Exclusion criteria included rearrangements involving SOX genes, mutations in either WNT4 or RSPO1, proven or suspected congenital adrenal hyperplasia (CAH), or the presence of SRY. All samples underwent array comparative genomic hybridization to confirm normal ploidy. Of the 79 children studied, 74 had no additional syndromic features. Of the 5 children with additional features, 3 were unrelated children with OTDSD/TDSD and CHD (with or without BPES), one had 46,XX TDSD with cerebral leukodystrophy, and another had 46,XX TDSD with multiple congenital anomalies, learning difficulties, and alopecia.
Analysis of exome sequencing datasets identified two individuals (individuals 1 and 2) with near-identical heterozygous frameshift mutations in NR2F2 (GenBank: NM_021005.3), c.103_109delGGCGCCC (p.Gly35Argfs∗75), and c.97_103delCCGCCCG (p.Pro33Alafs∗77) (Table 1). These mutations were not present in parental DNA and hence are de novo. No other shared genes carrying de novo mutations were identified in the datasets. The mutations are predicted to result in the generation of a downstream termination codon (Figures 1A and 1F). Both children presented with suspected OTDSD/TDSD (Table 1) and congenital heart disease (CHD). Individual 1 had a left congenital diaphragmatic hernia (CDH) and died shortly after birth due to hypoplasia of the left heart. Analysis of an additional 10 individuals with 46,XX OTDSD/TDSD, for whom there was insufficient DNA for complete exome studies, revealed a third unrelated child with OTDSD and CHD harboring the c.97_103delCCGCCCG (p.Pro33Alafs∗77) mutation (Table 1, individual 3). Since the parents of this child were unavailable for study, the mode of transmission of the mutation is unknown. The diagnosis of 46,XX OTDSD was confirmed by histology of the gonad (Figure 1B). Individuals 2 and 3 also had BPES (Figure 1C). In all three children, potentially pathogenic mutations were not identified in any other genes known to be involved in DSD and high-resolution array comparative genomic hybridization (aCGH) did not indicate rearrangements involving DSD-associated genes. These frameshift mutations are absent from the public variant databases and they were detected only in the three individuals in the cohort who had cardiac anomalies together with 46,XX DSD.
Figure 1 Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed by MRI.
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
Table 1 Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
NR2F2 is one the most conserved genes in the human genome and is intolerant to protein-truncating variants.14 To exclude the possibility that these NR2F2 mutations may be a chance finding, we performed Fisher’s exact tests (two-tailed) on the frequency of protein-truncating mutations found in the case subjects and compared this to rare missense mutations from 6,489 control European American and African American cohorts in the NHLBI-ESP project. A rare variant is defined as a variant with an allelic frequency of <1% in publically available databases. We found no protein-truncating mutations present in the control populations. We found a highly significant enrichment for the NR2F2 protein-truncating mutations identified in the three 46,XX DSD-affected case subjects compared to the absence of protein-truncating mutations in the control cohort (Fisher’s exact test, two-tailed p = 1.1 × 10−6). Even if we consider the five missense mutations present in the control population, the finding of three frameshift mutations in the 46,XX DSD cohort is still highly significant (p = 6 × 10−5). The genetic evidence in favor of causality is more compelling when one considers that the protein-truncating mutations were specifically identified only in the three children presenting with CHD and 46,XX DSD (p = 2.44 × 10−8).
NR2F2 encodes a key nuclear receptor, COUP-TF2.12 All three frameshift mutations are present in the N-terminal region of the protein and result in a downstream premature termination codon. RNA containing these mutations is predicted to be degraded by nonsense-mediated decay. Even if a truncated protein is produced, it would have severely impaired biological activity since the protein would lack both the DNA- and ligand-binding domains (Figure 1F). An in silico analysis of the NR2F2 exon 1 with either of the two deletions using the tools Human Splicing Factor 3 (HSF3), Splice Predictor, and RegRNA indicated that neither the two deletions are predicted to generate cryptic splice sites.
Murine Coup-tf2 protein has been reported to accumulate during early ovary development in a distinct Foxl2-negative somatic cell precursor.15 Although data are limited, these cells with Coup-tf2 have been hypothesized to be either mesenchymal cells and/or to differentiate into theca cells.15 We therefore investigated the profile of protein localization of COUP-TF2 in the early developing human ovary. Human fetal ovaries were isolated from material available following elective termination of pregnancy during the first trimester at the Department of Gynaecology at Copenhagen University Hospital (Rigshospitalet) and Hvidovre Hospital, Denmark. The regional ethics committee approved this study (permit number H-1-2012-007) and women gave their informed written and oral consent. We observed widespread presence of COUP-TF2 in the stromal cell population of the ovary at gestational weeks (GW) 9+1 (Figures 2A–2C) and GW 9+5 (Figures 2D and 2E), whereas FOXL2 is limited to somatic cells of the fetal ovary (Figure 2). At these stages, co-immunofluorescence demonstrated that FOXL2 and COUP-TF2 appeared to be mutually exclusive at the cellular level (Figure 2). Furthermore, analysis of RNA expression in different tissues from adults reveals that NR2F2 is most highly expressed in the ovary and female reproductive tissues.16
Figure 2 Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
We provide compelling genetic evidence for a role of COUP-TF2 in early human ovary development. We identified three protein-truncating, complete loss-of-function mutations that are acting in a dominant fashion. These findings indicate that NR2F2 may function in a dosage-sensitive manner, which is similar to other gene mutations known to disrupt human sex determination. This indicates that COUP-TF2 may be required to establish ovary identity during early human gonad development by the repression of genes involved in testis determination.
In mice, Coup-Tf2 is involved in the development of multiple organs and tissues by modulating the expression of downstream targets to promote cellular differentiation, proliferation, migration, survival, and intercellular communication.12, 17, 18, 19, 20 Globally, Coup-tf2 is highly abundant at E14-E15 in the mesenchymal compartment of the developing organs and declines after the completion of organogenesis.12 The absence of Coup-tf2 in terminally differentiated epithelium suggests that Coup-tf2 plays a major role in the mesenchymal-epithelial transition. Mice lacking Coup-tf2 die around E10 due to defects of angiogenesis and heart development.20 Recently, ten human heterozygous missense, in-frame duplication, or splice donor mutations in NR2F2 were reported in association with cardiac defects (CHD [MIM: 615779]).21, 22 Of these mutations, four were confirmed as de novo. Most children with NR2F2 mutations had atrioventricular septal defects, including a child with a hypoplastic left heart, which is consistent with the cardiac phenotypes of the children in this study. However, non-cardiac defects, such as virilization or BPES, were not described in these cohorts. In our study, individual 1 also presented with a left-sided diaphragmatic hernia (CDH). The p.Pro33Alafs∗77 variant was reported in a child with ASD, exotropia, and left-sided CDH, suggesting that CDH is part of the phenotypic spectrum associated with NR2F2 mutations.23
The BPES phenotype observed in children with NR2F2 mutations is strikingly similar to that associated with dominant mutations in FOXL2. These pathogenic variants cause BPES frequently together with 46,XX premature ovarian insufficiency but testis development has not been reported. BPES is thought to originate following developmental defects in peri-ocular mesenchymal cells, which are required to form the levator smooth muscle, tarsus, and Meibomian glands. Coup-tf2 is known to play crucial roles in the formation of the morphology of the murine eye, and given the similarities in the phenotypes, it would be of interest to determine whether FOXL2 and COUP-TF2 are acting in the same developmental pathway.24
In contrast to cardiac development, the role(s) of COUP-TF2 in early gonad development has yet to be fully defined. In the developing fetal rat testis, partial inhibition of Coup-tf2 by phthalates causes expansion of Leydig cells and an increase in the intratesticular testosterone concentration, consistent with Coup-tf2 being a factor repressing fetal androgenization.19 The protein localization of COUP-TF2 in human fetal Leydig cells during the first and second trimester could also be consistent with a similar role of COUP-TF2 in repression of androgen production.19, 25 Indeed, there is a large body of evidence from early studies to indicate that COUP-TF2 functions as a transcriptional repressor of pro-testis genes.26
Data are also emerging for the role of Coup-Tf2 in female reproductive development in mice but there seem to be clear differences with humans. Murine Coup-Tf2+/− XX females show a wide range of reproductive anomalies including reduced fecundity, irregular estrus cycles, delayed puberty, retarded postnatal growth, and reduced levels of steroidogenic enzymes, but virilization and testis development has not been reported.27 Recently, a tamoxifen-inducible Wt1CreERT2 mouse model that targets Nr2f2 in Wt1+ mesenchymal cells was described, where knockout XX mice had both Müllerian and Wolffian ducts in the mesonephros.28 The ovaries of the mice lacking Nr2f2 did not produce androgens, but an androgen-independent activation of the p-ERK pathway in the Wolffian duct epithelium was observed, leading to its maintenance in XX mice. In striking contrast to the mouse model, virilization of the genitalia in the three children reported here was associated with elevated levels of both testosterone and AMH and in one child the presence of testicular tissue was confirmed by gonad histology.
The mechanism responsible for testis development associated with COUP-TF2 variants remains to be defined. Consistent with the Z-theory of a double repressor model of human sex determination, COUP-TF2 acts both positively and negatively to modulate the expression of genes involved in sex determination in other cellular and organ contexts. For example, in the human endometrium, COUP-TF2 is a positive regulator of the pro-ovary WNT4 gene and in mice Coup-tf2 negatively regulates the expression of the pro-testis Sox9 gene in the osteogenic mesenchyme.29, 30
In addition to revealing unforeseen mechanisms in sex development, our study also highlights the importance of nuclear receptors (NR) in human development and disease. Humans have 48 different NRs with a diverse range of functions and next-generation sequencing approaches are starting to identify novel and sometimes unexpected phenotypes associated with specific NR variants.31 Recently, we described recurrent missense mutations that specifically target the Arg92 residue of another nuclear receptor, NR5A1 and which are associated with both 46,XX OTDSD and TDSD in multiple individuals.32 When this mutation is introduced into the XX mouse, it does not result in testis formation.33 The data presented here provide additional evidence of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have divergent functions in mouse and human biology.
|
|
sec
|
Main Text
The sex chromosomes of an individual usually direct gonadal sex development toward either a testis or ovary pathway. In 46,XY individuals, the presence of the Y chromosome testis-determining gene SRY (MIM: 601947) triggers a genetic cascade that both initiates testis formation and represses the formation of the ovary.1 Although many factors are known to be involved in early testis development, far less is known about genetic factors controlling the ovary.1 However, emerging evidence suggests that ovary development involves more than just a default (passive) pathway,2 consistent with the Z-factor theory proposed 25 years ago that the XX gonad expresses an elusive factor that actively promotes both “anti-testis” and “pro-ovary” functions.3
The genomic analysis of 46,XX individuals with testes (sometimes known as testicular disorders/differences of sex development [TDSD]; [MIM: 400045]) or ovotestes (ovotesticular DSD [OTDSD]) supports the hypothesis that “pro-testis/anti-ovary” or “pro-ovary/anti-testis” genetic pathways exist.4, 5, 6 These children typically present with virilized genitalia due to testosterone production from the presence of testicular tissue. Many individuals with TDSD and a minority with OTDSD have a translocation of the testis-determining SRY gene, usually onto one of the X chromosomes, whereas a small proportion have chromosomal rearrangements associated with upregulation (gain-of-function) of SOX gene expression (e.g., duplications of the RevSex [MIM: 616425] enhancer of SOX9 [MIM: 608160] and rearrangements of the SOX3 locus [MIM: 800833]).5, 6 This ectopic SOX gene expression increases “pro-testis” factors in the early developing ovary and results in a reprogramming of cellular sex identity to testis-typical Sertoli cells. Other rare forms of 46,XX DSD can occur due to mutations (loss-of-function) involving genes that are “pro-ovary/anti-testis.” The best example of this is in the WNT4/RSPO1 signaling pathway, which stabilizes β-catenin and is required for ovary development.7 Very rare heterozygous or homozygous mutations in WNT4 (MIM: 603490) cause Müllerian aplasia/hyperandrogenism (MIM: 158330)8 or testis development (SERKAL syndrome [MIM: 611812]) in 46,XX individuals, respectively, whereas homozygous RSPO1 (MIM: 609595) mutations are also associated with testis formation and skin phenotypes in 46,XX children (MIM: 610644).7 FOXL2 (MIM: 605597) is a forkhead/winged helix transcription factor, which is also a potential “pro-ovary” and “anti-testis” gene. Goat XX fetuses lacking Foxl2 have gonads resembling testes and the induced absence of Foxl2 in adult XX mice results in trans-differentiation of the ovaries into a testis-like gonad.9, 10, 11 In humans, heterozygous loss-of-function FOXL2 mutations are associated with autosomal-dominant blepharophimosis-ptosis-epicanthus inversus syndrome (BPES [MIM: 110100]) either with (type I) or without (type 2) ovarian insufficiency as well as ovarian insufficiency without BPES (MIM: 608996), but homozygous FOXL2 disruption has not been described.10 The limited understanding of the genes involved in ovary formation means that for most children with OTDSD/TDSD, the molecular basis is currently unknown.
Here, we report the molecular etiology of a syndromic form of 46,XX DSD that includes genital virilization, congenital heart disease (CHD), and variable somatic anomalies including BPES and congenital diaphragmatic hernia (CDH). This syndrome is caused by protein-truncating mutations in the orphan nuclear receptor NR2F2 (MIM: 107773). NR2F2 encodes the transcription factor chicken ovalbumin upstream promoter transcription factor 2 (COUP-TF2).12 Our data indicate that in the early developing human chromosomal female XX gonad, COUP-TF2 is a human “pro-ovary” and “anti-testis” sex-determining factor.
Following written informed consent and with local ethics committee approvals, whole-exome sequencing was performed on 69 46,XX individuals with either unexplained virilization (n = 14) or unexplained OTDSD/TDSD (n = 55) as described elsewhere.13 Sanger sequencing of NR2F2 was performed on DNA from a further 10 individuals with 46,XX OTDSD/TDSD where there was insufficient DNA for complete exome analysis. Exclusion criteria included rearrangements involving SOX genes, mutations in either WNT4 or RSPO1, proven or suspected congenital adrenal hyperplasia (CAH), or the presence of SRY. All samples underwent array comparative genomic hybridization to confirm normal ploidy. Of the 79 children studied, 74 had no additional syndromic features. Of the 5 children with additional features, 3 were unrelated children with OTDSD/TDSD and CHD (with or without BPES), one had 46,XX TDSD with cerebral leukodystrophy, and another had 46,XX TDSD with multiple congenital anomalies, learning difficulties, and alopecia.
Analysis of exome sequencing datasets identified two individuals (individuals 1 and 2) with near-identical heterozygous frameshift mutations in NR2F2 (GenBank: NM_021005.3), c.103_109delGGCGCCC (p.Gly35Argfs∗75), and c.97_103delCCGCCCG (p.Pro33Alafs∗77) (Table 1). These mutations were not present in parental DNA and hence are de novo. No other shared genes carrying de novo mutations were identified in the datasets. The mutations are predicted to result in the generation of a downstream termination codon (Figures 1A and 1F). Both children presented with suspected OTDSD/TDSD (Table 1) and congenital heart disease (CHD). Individual 1 had a left congenital diaphragmatic hernia (CDH) and died shortly after birth due to hypoplasia of the left heart. Analysis of an additional 10 individuals with 46,XX OTDSD/TDSD, for whom there was insufficient DNA for complete exome studies, revealed a third unrelated child with OTDSD and CHD harboring the c.97_103delCCGCCCG (p.Pro33Alafs∗77) mutation (Table 1, individual 3). Since the parents of this child were unavailable for study, the mode of transmission of the mutation is unknown. The diagnosis of 46,XX OTDSD was confirmed by histology of the gonad (Figure 1B). Individuals 2 and 3 also had BPES (Figure 1C). In all three children, potentially pathogenic mutations were not identified in any other genes known to be involved in DSD and high-resolution array comparative genomic hybridization (aCGH) did not indicate rearrangements involving DSD-associated genes. These frameshift mutations are absent from the public variant databases and they were detected only in the three individuals in the cohort who had cardiac anomalies together with 46,XX DSD.
Figure 1 Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed by MRI.
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
Table 1 Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
NR2F2 is one the most conserved genes in the human genome and is intolerant to protein-truncating variants.14 To exclude the possibility that these NR2F2 mutations may be a chance finding, we performed Fisher’s exact tests (two-tailed) on the frequency of protein-truncating mutations found in the case subjects and compared this to rare missense mutations from 6,489 control European American and African American cohorts in the NHLBI-ESP project. A rare variant is defined as a variant with an allelic frequency of <1% in publically available databases. We found no protein-truncating mutations present in the control populations. We found a highly significant enrichment for the NR2F2 protein-truncating mutations identified in the three 46,XX DSD-affected case subjects compared to the absence of protein-truncating mutations in the control cohort (Fisher’s exact test, two-tailed p = 1.1 × 10−6). Even if we consider the five missense mutations present in the control population, the finding of three frameshift mutations in the 46,XX DSD cohort is still highly significant (p = 6 × 10−5). The genetic evidence in favor of causality is more compelling when one considers that the protein-truncating mutations were specifically identified only in the three children presenting with CHD and 46,XX DSD (p = 2.44 × 10−8).
NR2F2 encodes a key nuclear receptor, COUP-TF2.12 All three frameshift mutations are present in the N-terminal region of the protein and result in a downstream premature termination codon. RNA containing these mutations is predicted to be degraded by nonsense-mediated decay. Even if a truncated protein is produced, it would have severely impaired biological activity since the protein would lack both the DNA- and ligand-binding domains (Figure 1F). An in silico analysis of the NR2F2 exon 1 with either of the two deletions using the tools Human Splicing Factor 3 (HSF3), Splice Predictor, and RegRNA indicated that neither the two deletions are predicted to generate cryptic splice sites.
Murine Coup-tf2 protein has been reported to accumulate during early ovary development in a distinct Foxl2-negative somatic cell precursor.15 Although data are limited, these cells with Coup-tf2 have been hypothesized to be either mesenchymal cells and/or to differentiate into theca cells.15 We therefore investigated the profile of protein localization of COUP-TF2 in the early developing human ovary. Human fetal ovaries were isolated from material available following elective termination of pregnancy during the first trimester at the Department of Gynaecology at Copenhagen University Hospital (Rigshospitalet) and Hvidovre Hospital, Denmark. The regional ethics committee approved this study (permit number H-1-2012-007) and women gave their informed written and oral consent. We observed widespread presence of COUP-TF2 in the stromal cell population of the ovary at gestational weeks (GW) 9+1 (Figures 2A–2C) and GW 9+5 (Figures 2D and 2E), whereas FOXL2 is limited to somatic cells of the fetal ovary (Figure 2). At these stages, co-immunofluorescence demonstrated that FOXL2 and COUP-TF2 appeared to be mutually exclusive at the cellular level (Figure 2). Furthermore, analysis of RNA expression in different tissues from adults reveals that NR2F2 is most highly expressed in the ovary and female reproductive tissues.16
Figure 2 Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
We provide compelling genetic evidence for a role of COUP-TF2 in early human ovary development. We identified three protein-truncating, complete loss-of-function mutations that are acting in a dominant fashion. These findings indicate that NR2F2 may function in a dosage-sensitive manner, which is similar to other gene mutations known to disrupt human sex determination. This indicates that COUP-TF2 may be required to establish ovary identity during early human gonad development by the repression of genes involved in testis determination.
In mice, Coup-Tf2 is involved in the development of multiple organs and tissues by modulating the expression of downstream targets to promote cellular differentiation, proliferation, migration, survival, and intercellular communication.12, 17, 18, 19, 20 Globally, Coup-tf2 is highly abundant at E14-E15 in the mesenchymal compartment of the developing organs and declines after the completion of organogenesis.12 The absence of Coup-tf2 in terminally differentiated epithelium suggests that Coup-tf2 plays a major role in the mesenchymal-epithelial transition. Mice lacking Coup-tf2 die around E10 due to defects of angiogenesis and heart development.20 Recently, ten human heterozygous missense, in-frame duplication, or splice donor mutations in NR2F2 were reported in association with cardiac defects (CHD [MIM: 615779]).21, 22 Of these mutations, four were confirmed as de novo. Most children with NR2F2 mutations had atrioventricular septal defects, including a child with a hypoplastic left heart, which is consistent with the cardiac phenotypes of the children in this study. However, non-cardiac defects, such as virilization or BPES, were not described in these cohorts. In our study, individual 1 also presented with a left-sided diaphragmatic hernia (CDH). The p.Pro33Alafs∗77 variant was reported in a child with ASD, exotropia, and left-sided CDH, suggesting that CDH is part of the phenotypic spectrum associated with NR2F2 mutations.23
The BPES phenotype observed in children with NR2F2 mutations is strikingly similar to that associated with dominant mutations in FOXL2. These pathogenic variants cause BPES frequently together with 46,XX premature ovarian insufficiency but testis development has not been reported. BPES is thought to originate following developmental defects in peri-ocular mesenchymal cells, which are required to form the levator smooth muscle, tarsus, and Meibomian glands. Coup-tf2 is known to play crucial roles in the formation of the morphology of the murine eye, and given the similarities in the phenotypes, it would be of interest to determine whether FOXL2 and COUP-TF2 are acting in the same developmental pathway.24
In contrast to cardiac development, the role(s) of COUP-TF2 in early gonad development has yet to be fully defined. In the developing fetal rat testis, partial inhibition of Coup-tf2 by phthalates causes expansion of Leydig cells and an increase in the intratesticular testosterone concentration, consistent with Coup-tf2 being a factor repressing fetal androgenization.19 The protein localization of COUP-TF2 in human fetal Leydig cells during the first and second trimester could also be consistent with a similar role of COUP-TF2 in repression of androgen production.19, 25 Indeed, there is a large body of evidence from early studies to indicate that COUP-TF2 functions as a transcriptional repressor of pro-testis genes.26
Data are also emerging for the role of Coup-Tf2 in female reproductive development in mice but there seem to be clear differences with humans. Murine Coup-Tf2+/− XX females show a wide range of reproductive anomalies including reduced fecundity, irregular estrus cycles, delayed puberty, retarded postnatal growth, and reduced levels of steroidogenic enzymes, but virilization and testis development has not been reported.27 Recently, a tamoxifen-inducible Wt1CreERT2 mouse model that targets Nr2f2 in Wt1+ mesenchymal cells was described, where knockout XX mice had both Müllerian and Wolffian ducts in the mesonephros.28 The ovaries of the mice lacking Nr2f2 did not produce androgens, but an androgen-independent activation of the p-ERK pathway in the Wolffian duct epithelium was observed, leading to its maintenance in XX mice. In striking contrast to the mouse model, virilization of the genitalia in the three children reported here was associated with elevated levels of both testosterone and AMH and in one child the presence of testicular tissue was confirmed by gonad histology.
The mechanism responsible for testis development associated with COUP-TF2 variants remains to be defined. Consistent with the Z-theory of a double repressor model of human sex determination, COUP-TF2 acts both positively and negatively to modulate the expression of genes involved in sex determination in other cellular and organ contexts. For example, in the human endometrium, COUP-TF2 is a positive regulator of the pro-ovary WNT4 gene and in mice Coup-tf2 negatively regulates the expression of the pro-testis Sox9 gene in the osteogenic mesenchyme.29, 30
In addition to revealing unforeseen mechanisms in sex development, our study also highlights the importance of nuclear receptors (NR) in human development and disease. Humans have 48 different NRs with a diverse range of functions and next-generation sequencing approaches are starting to identify novel and sometimes unexpected phenotypes associated with specific NR variants.31 Recently, we described recurrent missense mutations that specifically target the Arg92 residue of another nuclear receptor, NR5A1 and which are associated with both 46,XX OTDSD and TDSD in multiple individuals.32 When this mutation is introduced into the XX mouse, it does not result in testis formation.33 The data presented here provide additional evidence of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have divergent functions in mouse and human biology.
|
|
title
|
Main Text
|
|
p
|
The sex chromosomes of an individual usually direct gonadal sex development toward either a testis or ovary pathway. In 46,XY individuals, the presence of the Y chromosome testis-determining gene SRY (MIM: 601947) triggers a genetic cascade that both initiates testis formation and represses the formation of the ovary.1 Although many factors are known to be involved in early testis development, far less is known about genetic factors controlling the ovary.1 However, emerging evidence suggests that ovary development involves more than just a default (passive) pathway,2 consistent with the Z-factor theory proposed 25 years ago that the XX gonad expresses an elusive factor that actively promotes both “anti-testis” and “pro-ovary” functions.3
|
|
p
|
The genomic analysis of 46,XX individuals with testes (sometimes known as testicular disorders/differences of sex development [TDSD]; [MIM: 400045]) or ovotestes (ovotesticular DSD [OTDSD]) supports the hypothesis that “pro-testis/anti-ovary” or “pro-ovary/anti-testis” genetic pathways exist.4, 5, 6 These children typically present with virilized genitalia due to testosterone production from the presence of testicular tissue. Many individuals with TDSD and a minority with OTDSD have a translocation of the testis-determining SRY gene, usually onto one of the X chromosomes, whereas a small proportion have chromosomal rearrangements associated with upregulation (gain-of-function) of SOX gene expression (e.g., duplications of the RevSex [MIM: 616425] enhancer of SOX9 [MIM: 608160] and rearrangements of the SOX3 locus [MIM: 800833]).5, 6 This ectopic SOX gene expression increases “pro-testis” factors in the early developing ovary and results in a reprogramming of cellular sex identity to testis-typical Sertoli cells. Other rare forms of 46,XX DSD can occur due to mutations (loss-of-function) involving genes that are “pro-ovary/anti-testis.” The best example of this is in the WNT4/RSPO1 signaling pathway, which stabilizes β-catenin and is required for ovary development.7 Very rare heterozygous or homozygous mutations in WNT4 (MIM: 603490) cause Müllerian aplasia/hyperandrogenism (MIM: 158330)8 or testis development (SERKAL syndrome [MIM: 611812]) in 46,XX individuals, respectively, whereas homozygous RSPO1 (MIM: 609595) mutations are also associated with testis formation and skin phenotypes in 46,XX children (MIM: 610644).7 FOXL2 (MIM: 605597) is a forkhead/winged helix transcription factor, which is also a potential “pro-ovary” and “anti-testis” gene. Goat XX fetuses lacking Foxl2 have gonads resembling testes and the induced absence of Foxl2 in adult XX mice results in trans-differentiation of the ovaries into a testis-like gonad.9, 10, 11 In humans, heterozygous loss-of-function FOXL2 mutations are associated with autosomal-dominant blepharophimosis-ptosis-epicanthus inversus syndrome (BPES [MIM: 110100]) either with (type I) or without (type 2) ovarian insufficiency as well as ovarian insufficiency without BPES (MIM: 608996), but homozygous FOXL2 disruption has not been described.10 The limited understanding of the genes involved in ovary formation means that for most children with OTDSD/TDSD, the molecular basis is currently unknown.
|
|
p
|
Here, we report the molecular etiology of a syndromic form of 46,XX DSD that includes genital virilization, congenital heart disease (CHD), and variable somatic anomalies including BPES and congenital diaphragmatic hernia (CDH). This syndrome is caused by protein-truncating mutations in the orphan nuclear receptor NR2F2 (MIM: 107773). NR2F2 encodes the transcription factor chicken ovalbumin upstream promoter transcription factor 2 (COUP-TF2).12 Our data indicate that in the early developing human chromosomal female XX gonad, COUP-TF2 is a human “pro-ovary” and “anti-testis” sex-determining factor.
|
|
p
|
Following written informed consent and with local ethics committee approvals, whole-exome sequencing was performed on 69 46,XX individuals with either unexplained virilization (n = 14) or unexplained OTDSD/TDSD (n = 55) as described elsewhere.13 Sanger sequencing of NR2F2 was performed on DNA from a further 10 individuals with 46,XX OTDSD/TDSD where there was insufficient DNA for complete exome analysis. Exclusion criteria included rearrangements involving SOX genes, mutations in either WNT4 or RSPO1, proven or suspected congenital adrenal hyperplasia (CAH), or the presence of SRY. All samples underwent array comparative genomic hybridization to confirm normal ploidy. Of the 79 children studied, 74 had no additional syndromic features. Of the 5 children with additional features, 3 were unrelated children with OTDSD/TDSD and CHD (with or without BPES), one had 46,XX TDSD with cerebral leukodystrophy, and another had 46,XX TDSD with multiple congenital anomalies, learning difficulties, and alopecia.
|
|
p
|
Analysis of exome sequencing datasets identified two individuals (individuals 1 and 2) with near-identical heterozygous frameshift mutations in NR2F2 (GenBank: NM_021005.3), c.103_109delGGCGCCC (p.Gly35Argfs∗75), and c.97_103delCCGCCCG (p.Pro33Alafs∗77) (Table 1). These mutations were not present in parental DNA and hence are de novo. No other shared genes carrying de novo mutations were identified in the datasets. The mutations are predicted to result in the generation of a downstream termination codon (Figures 1A and 1F). Both children presented with suspected OTDSD/TDSD (Table 1) and congenital heart disease (CHD). Individual 1 had a left congenital diaphragmatic hernia (CDH) and died shortly after birth due to hypoplasia of the left heart. Analysis of an additional 10 individuals with 46,XX OTDSD/TDSD, for whom there was insufficient DNA for complete exome studies, revealed a third unrelated child with OTDSD and CHD harboring the c.97_103delCCGCCCG (p.Pro33Alafs∗77) mutation (Table 1, individual 3). Since the parents of this child were unavailable for study, the mode of transmission of the mutation is unknown. The diagnosis of 46,XX OTDSD was confirmed by histology of the gonad (Figure 1B). Individuals 2 and 3 also had BPES (Figure 1C). In all three children, potentially pathogenic mutations were not identified in any other genes known to be involved in DSD and high-resolution array comparative genomic hybridization (aCGH) did not indicate rearrangements involving DSD-associated genes. These frameshift mutations are absent from the public variant databases and they were detected only in the three individuals in the cohort who had cardiac anomalies together with 46,XX DSD.
Figure 1 Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed by MRI.
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
Table 1 Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
|
|
figure
|
Figure 1 Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed by MRI.
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
|
|
label
|
Figure 1
|
|
caption
|
Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed by MRI.
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
|
|
p
|
Identification of Three Individuals with 46,XX DSD and Heterozygous Frameshift Mutations in NR2F2
|
|
p
|
(A) Representative Sanger sequence chromatograms of individuals 1–3 showing the positions of the frameshift mutations.
|
|
p
|
(B) Histology of the right gonad of individual 3 showing testicular tubule-like structures surrounded by stromal-like tissue (scale bar corresponds to 100 μm).
|
|
p
|
(C) Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) of individual 3.
|
|
p
|
(D) Uterus (arrow) of individual 2 observed by MRI.
|
|
p
|
(E) Pelvic radiography of individual 3 showing the vagina (V) and a short urogenital sinus (UrS).
|
|
p
|
(F) Schematic representation of COUP-TF2 showing the main functional domains and the position and downstream consequences of the three frameshift mutations. The first zinc finger motif is highlighted in green in the sequence alignment. The transcript ID is GenBank: NM_021005.3.
|
|
table-wrap
|
Table 1 Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
|
|
label
|
Table 1
|
|
caption
|
Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
|
|
p
|
Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
|
|
table
|
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
|
|
tr
|
Variable Individual 1 Individual 2 Individual 3
|
|
th
|
Variable
|
|
th
|
Individual 1
|
|
th
|
Individual 2
|
|
th
|
Individual 3
|
|
tr
|
Ancestry Latino Senegalese Hungarian
|
|
td
|
Ancestry
|
|
td
|
Latino
|
|
td
|
Senegalese
|
|
td
|
Hungarian
|
|
tr
|
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
|
|
td
|
Karyotype
|
|
td
|
46,XX SRY-negative
|
|
td
|
46,XX SRY-negative
|
|
td
|
46,XX SRY-negative
|
|
tr
|
Birth weight (kg) 2.6 2.05 N/A
|
|
td
|
Birth weight (kg)
|
|
td
|
2.6
|
|
td
|
2.05
|
|
td
|
N/A
|
|
tr
|
Cardiac hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function persistent ostium secundum and ASD VSD at birth; spontaneous closure of VSD at 9 years of age
|
|
td
|
Cardiac
|
|
td
|
hypoplastic L heart at birth; severely dilated R ventricle with moderate RVH and mild to moderately depressed RV systolic function
|
|
td
|
persistent ostium secundum and ASD
|
|
td
|
VSD at birth; spontaneous closure of VSD at 9 years of age
|
|
tr
|
External genitalia male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable “ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable “ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
|
|
td
|
External genitalia
|
|
td
|
male, hyperpigmented; phallus 3 cm with no hypospadias; gonads not palpable
|
|
td
|
“ambiguous” with phallus-like clitoris, pigmented scrotum; gonads not palpable
|
|
td
|
“ambiguous” Prader IV, pigmented scrotum, phallus-like clitoris; R, palpable gonad in the inguinal canal
|
|
tr
|
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
|
|
td
|
Internal genitalia
|
|
td
|
uterus not identified by US
|
|
td
|
uterus present
|
|
td
|
R, ductus-like Wolffian structures; L, uterus, ovary, and Fallopian tube; vagina and short urogenital sinus
|
|
tr
|
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
|
|
td
|
Gonads
|
|
td
|
not observed by US
|
|
td
|
not observed by US or MRI
|
|
td
|
pelvic ultrasound: R testis, L ovary; histology: R gonad, testis tubules, and ovarian tissue with oocytes
|
|
tr
|
Other somatic anomalies left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb anomalies, hypertelorism, BPES
|
|
td
|
Other somatic anomalies
|
|
td
|
left congenital diaphragmatic hernia
|
|
td
|
BPES
|
|
td
|
mild learning disabilities, minor limb anomalies, hypertelorism, BPES
|
|
tr
|
Endocrine data (reference values) Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1) Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
|
|
td
|
Endocrine data (reference values)
|
|
td
|
Day 1: T, 135 ng/dL (20–64); 17-OHP, 120 ng/dL (11–170); LH, 5.1 IU/L (0.02–7.0); FSH, 1.1 IU/L (0.16–4.1)
|
|
td
|
Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL (<4.2); Inhibin B, 263 pg/mL (<110); FSH, 13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3); 17-OHP, 127 ng/dL (<270)Day 15: T, 327 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH, 5.1 IU/L (0.9–3); estradiol <5 pg/mL1 month: T, 304 ng/dL (<40); AMH, 43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL (<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L (0.9–3); estradiol, <5 pg/mL
|
|
td
|
Day 17: T, 250 ng/dL (<40); 17-OHP, 185 ng/dL (40–490)Day 30: T, 460 ng/dL (<40)Day 45: T, 50 ng/dL (<40)Day 73: T, 110 ng/dL (<40)
|
|
tr
|
Mutation de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75) de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77) N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
|
|
td
|
Mutation
|
|
td
|
de novo, c.103_109delGGCGCCC (p.Gly35Argfs∗75)
|
|
td
|
de novo, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
|
|
td
|
N/A, c.97_103delCCGCCCG (p.Pro33Alafs∗77)
|
|
table-wrap-foot
|
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
|
|
footnote
|
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
|
|
p
|
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors: testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
|
|
footnote
|
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
|
|
p
|
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome; AMH, anti-Müllerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia (e.g., 17-OHP) were negative.
|
|
p
|
NR2F2 is one the most conserved genes in the human genome and is intolerant to protein-truncating variants.14 To exclude the possibility that these NR2F2 mutations may be a chance finding, we performed Fisher’s exact tests (two-tailed) on the frequency of protein-truncating mutations found in the case subjects and compared this to rare missense mutations from 6,489 control European American and African American cohorts in the NHLBI-ESP project. A rare variant is defined as a variant with an allelic frequency of <1% in publically available databases. We found no protein-truncating mutations present in the control populations. We found a highly significant enrichment for the NR2F2 protein-truncating mutations identified in the three 46,XX DSD-affected case subjects compared to the absence of protein-truncating mutations in the control cohort (Fisher’s exact test, two-tailed p = 1.1 × 10−6). Even if we consider the five missense mutations present in the control population, the finding of three frameshift mutations in the 46,XX DSD cohort is still highly significant (p = 6 × 10−5). The genetic evidence in favor of causality is more compelling when one considers that the protein-truncating mutations were specifically identified only in the three children presenting with CHD and 46,XX DSD (p = 2.44 × 10−8).
|
|
p
|
NR2F2 encodes a key nuclear receptor, COUP-TF2.12 All three frameshift mutations are present in the N-terminal region of the protein and result in a downstream premature termination codon. RNA containing these mutations is predicted to be degraded by nonsense-mediated decay. Even if a truncated protein is produced, it would have severely impaired biological activity since the protein would lack both the DNA- and ligand-binding domains (Figure 1F). An in silico analysis of the NR2F2 exon 1 with either of the two deletions using the tools Human Splicing Factor 3 (HSF3), Splice Predictor, and RegRNA indicated that neither the two deletions are predicted to generate cryptic splice sites.
|
|
p
|
Murine Coup-tf2 protein has been reported to accumulate during early ovary development in a distinct Foxl2-negative somatic cell precursor.15 Although data are limited, these cells with Coup-tf2 have been hypothesized to be either mesenchymal cells and/or to differentiate into theca cells.15 We therefore investigated the profile of protein localization of COUP-TF2 in the early developing human ovary. Human fetal ovaries were isolated from material available following elective termination of pregnancy during the first trimester at the Department of Gynaecology at Copenhagen University Hospital (Rigshospitalet) and Hvidovre Hospital, Denmark. The regional ethics committee approved this study (permit number H-1-2012-007) and women gave their informed written and oral consent. We observed widespread presence of COUP-TF2 in the stromal cell population of the ovary at gestational weeks (GW) 9+1 (Figures 2A–2C) and GW 9+5 (Figures 2D and 2E), whereas FOXL2 is limited to somatic cells of the fetal ovary (Figure 2). At these stages, co-immunofluorescence demonstrated that FOXL2 and COUP-TF2 appeared to be mutually exclusive at the cellular level (Figure 2). Furthermore, analysis of RNA expression in different tissues from adults reveals that NR2F2 is most highly expressed in the ovary and female reproductive tissues.16
Figure 2 Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
|
|
figure
|
Figure 2 Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
|
|
label
|
Figure 2
|
|
caption
|
Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
|
|
p
|
Protein Localization of COUP-TF2 and FOXL2 during Early Human Ovarian Development
|
|
p
|
(A–C) Immunofluorescence showing protein localization of COUP-TF2 (green) and FOXL2 (red) at gestational week (GW) 9+1.
|
|
p
|
(D–F) Immunohistochemistry at GW 9+5. Extensive staining of COUP-FT2 is observed in the stromal cell population of the developing fetal ovary. At both stages there appears to be a mutually exclusive presence of FOXL2 and NR2F2, suggesting they mark different somatic cell populations.
|
|
p
|
Dashed box in (A) and (C) indicates the position of the expanded views. Nuclei are counterstained with DAPI. Fetal age was determined by scanning crown-rump length and by evaluation of foot length.34 Sex of fetal samples was determined by PCR for SRY as previously reported.35 Immunofluorescence was performed as previously described.36 Primary antibodies used were COUP-TFII/NR2F2 (Perseus Proteomics, PP-H7147-60, diluted 1:100) and FOXL2 (a kind gift from Dagmar Wilhelm, diluted 1:100). Negative controls were included and processed with the primary antibody replaced by the dilution buffer alone. None of the negative control slides showed staining. Fluorescent images were captured using an Olympus BX61 microscope (Olympus) with the Cell Sens Dimension software v.1.16.
|
|
p
|
We provide compelling genetic evidence for a role of COUP-TF2 in early human ovary development. We identified three protein-truncating, complete loss-of-function mutations that are acting in a dominant fashion. These findings indicate that NR2F2 may function in a dosage-sensitive manner, which is similar to other gene mutations known to disrupt human sex determination. This indicates that COUP-TF2 may be required to establish ovary identity during early human gonad development by the repression of genes involved in testis determination.
|
|
p
|
In mice, Coup-Tf2 is involved in the development of multiple organs and tissues by modulating the expression of downstream targets to promote cellular differentiation, proliferation, migration, survival, and intercellular communication.12, 17, 18, 19, 20 Globally, Coup-tf2 is highly abundant at E14-E15 in the mesenchymal compartment of the developing organs and declines after the completion of organogenesis.12 The absence of Coup-tf2 in terminally differentiated epithelium suggests that Coup-tf2 plays a major role in the mesenchymal-epithelial transition. Mice lacking Coup-tf2 die around E10 due to defects of angiogenesis and heart development.20 Recently, ten human heterozygous missense, in-frame duplication, or splice donor mutations in NR2F2 were reported in association with cardiac defects (CHD [MIM: 615779]).21, 22 Of these mutations, four were confirmed as de novo. Most children with NR2F2 mutations had atrioventricular septal defects, including a child with a hypoplastic left heart, which is consistent with the cardiac phenotypes of the children in this study. However, non-cardiac defects, such as virilization or BPES, were not described in these cohorts. In our study, individual 1 also presented with a left-sided diaphragmatic hernia (CDH). The p.Pro33Alafs∗77 variant was reported in a child with ASD, exotropia, and left-sided CDH, suggesting that CDH is part of the phenotypic spectrum associated with NR2F2 mutations.23
|
|
p
|
The BPES phenotype observed in children with NR2F2 mutations is strikingly similar to that associated with dominant mutations in FOXL2. These pathogenic variants cause BPES frequently together with 46,XX premature ovarian insufficiency but testis development has not been reported. BPES is thought to originate following developmental defects in peri-ocular mesenchymal cells, which are required to form the levator smooth muscle, tarsus, and Meibomian glands. Coup-tf2 is known to play crucial roles in the formation of the morphology of the murine eye, and given the similarities in the phenotypes, it would be of interest to determine whether FOXL2 and COUP-TF2 are acting in the same developmental pathway.24
|
|
p
|
In contrast to cardiac development, the role(s) of COUP-TF2 in early gonad development has yet to be fully defined. In the developing fetal rat testis, partial inhibition of Coup-tf2 by phthalates causes expansion of Leydig cells and an increase in the intratesticular testosterone concentration, consistent with Coup-tf2 being a factor repressing fetal androgenization.19 The protein localization of COUP-TF2 in human fetal Leydig cells during the first and second trimester could also be consistent with a similar role of COUP-TF2 in repression of androgen production.19, 25 Indeed, there is a large body of evidence from early studies to indicate that COUP-TF2 functions as a transcriptional repressor of pro-testis genes.26
|
|
p
|
Data are also emerging for the role of Coup-Tf2 in female reproductive development in mice but there seem to be clear differences with humans. Murine Coup-Tf2+/− XX females show a wide range of reproductive anomalies including reduced fecundity, irregular estrus cycles, delayed puberty, retarded postnatal growth, and reduced levels of steroidogenic enzymes, but virilization and testis development has not been reported.27 Recently, a tamoxifen-inducible Wt1CreERT2 mouse model that targets Nr2f2 in Wt1+ mesenchymal cells was described, where knockout XX mice had both Müllerian and Wolffian ducts in the mesonephros.28 The ovaries of the mice lacking Nr2f2 did not produce androgens, but an androgen-independent activation of the p-ERK pathway in the Wolffian duct epithelium was observed, leading to its maintenance in XX mice. In striking contrast to the mouse model, virilization of the genitalia in the three children reported here was associated with elevated levels of both testosterone and AMH and in one child the presence of testicular tissue was confirmed by gonad histology.
|
|
p
|
The mechanism responsible for testis development associated with COUP-TF2 variants remains to be defined. Consistent with the Z-theory of a double repressor model of human sex determination, COUP-TF2 acts both positively and negatively to modulate the expression of genes involved in sex determination in other cellular and organ contexts. For example, in the human endometrium, COUP-TF2 is a positive regulator of the pro-ovary WNT4 gene and in mice Coup-tf2 negatively regulates the expression of the pro-testis Sox9 gene in the osteogenic mesenchyme.29, 30
|
|
p
|
In addition to revealing unforeseen mechanisms in sex development, our study also highlights the importance of nuclear receptors (NR) in human development and disease. Humans have 48 different NRs with a diverse range of functions and next-generation sequencing approaches are starting to identify novel and sometimes unexpected phenotypes associated with specific NR variants.31 Recently, we described recurrent missense mutations that specifically target the Arg92 residue of another nuclear receptor, NR5A1 and which are associated with both 46,XX OTDSD and TDSD in multiple individuals.32 When this mutation is introduced into the XX mouse, it does not result in testis formation.33 The data presented here provide additional evidence of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have divergent functions in mouse and human biology.
|
|
back
|
Web Resources
ExAC Browser, http://exac.broadinstitute.org/
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
Human Splicing Finder, http://www.umd.be/HSF3/
NetGene2, http://www.cbs.dtu.dk/services/NetGene2/
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/
OMIM, http://www.omim.org/
RegRNA, http://regrna.mbc.nctu.edu.tw/html/prediction.html
The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000185551-NR2F2/tissue
Acknowledgments
A.B. is funded in part by the program Actions Concertees Interpasteuriennes (ACIP) and a research grant from the European Society of Pediatric Endocrinology. A.B. and K.McE. are funded by a research grant from the EuroDSD in the European Community’s Seventh Framework Programme FP7/2007-2013 under grant agreement no. 201444 as well as grant no. 295097 as part of the EU call FP7-INCO-2011-6. J.C.A. is a Wellcome Trust Senior Research Fellow in Clinical Science (grant 098513/Z/12/Z, 209328/Z/17/Z) with research support from Great Ormond Street Hospital Children's Charity (grant V2518) and the NIHR GOSH BRC (IS-BRC-1215-20012). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. This work is supported by the COST Action DSDnet BM1303. The authors wish to thank Dr. Etienne Patin for comments on the manuscript. This work was funded by the Agence Nationale de la Recherche (Laboratoire d’Excellence Revive, Investissement d’Avenir; ANR-10-LABX-73).
|
|
sec
|
Web Resources
ExAC Browser, http://exac.broadinstitute.org/
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
Human Splicing Finder, http://www.umd.be/HSF3/
NetGene2, http://www.cbs.dtu.dk/services/NetGene2/
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/
OMIM, http://www.omim.org/
RegRNA, http://regrna.mbc.nctu.edu.tw/html/prediction.html
The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000185551-NR2F2/tissue
|
|
title
|
Web Resources
|
|
p
|
ExAC Browser, http://exac.broadinstitute.org/
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
Human Splicing Finder, http://www.umd.be/HSF3/
NetGene2, http://www.cbs.dtu.dk/services/NetGene2/
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/
OMIM, http://www.omim.org/
RegRNA, http://regrna.mbc.nctu.edu.tw/html/prediction.html
The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000185551-NR2F2/tissue
|
|
p
|
ExAC Browser, http://exac.broadinstitute.org/
|
|
p
|
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
|
|
p
|
Human Splicing Finder, http://www.umd.be/HSF3/
|
|
p
|
NetGene2, http://www.cbs.dtu.dk/services/NetGene2/
|
|
p
|
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/
|
|
p
|
OMIM, http://www.omim.org/
|
|
p
|
RegRNA, http://regrna.mbc.nctu.edu.tw/html/prediction.html
|
|
p
|
The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000185551-NR2F2/tissue
|
|
ack
|
Acknowledgments
A.B. is funded in part by the program Actions Concertees Interpasteuriennes (ACIP) and a research grant from the European Society of Pediatric Endocrinology. A.B. and K.McE. are funded by a research grant from the EuroDSD in the European Community’s Seventh Framework Programme FP7/2007-2013 under grant agreement no. 201444 as well as grant no. 295097 as part of the EU call FP7-INCO-2011-6. J.C.A. is a Wellcome Trust Senior Research Fellow in Clinical Science (grant 098513/Z/12/Z, 209328/Z/17/Z) with research support from Great Ormond Street Hospital Children's Charity (grant V2518) and the NIHR GOSH BRC (IS-BRC-1215-20012). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. This work is supported by the COST Action DSDnet BM1303. The authors wish to thank Dr. Etienne Patin for comments on the manuscript. This work was funded by the Agence Nationale de la Recherche (Laboratoire d’Excellence Revive, Investissement d’Avenir; ANR-10-LABX-73).
|
|
title
|
Acknowledgments
|
|
p
|
A.B. is funded in part by the program Actions Concertees Interpasteuriennes (ACIP) and a research grant from the European Society of Pediatric Endocrinology. A.B. and K.McE. are funded by a research grant from the EuroDSD in the European Community’s Seventh Framework Programme FP7/2007-2013 under grant agreement no. 201444 as well as grant no. 295097 as part of the EU call FP7-INCO-2011-6. J.C.A. is a Wellcome Trust Senior Research Fellow in Clinical Science (grant 098513/Z/12/Z, 209328/Z/17/Z) with research support from Great Ormond Street Hospital Children's Charity (grant V2518) and the NIHR GOSH BRC (IS-BRC-1215-20012). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. This work is supported by the COST Action DSDnet BM1303. The authors wish to thank Dr. Etienne Patin for comments on the manuscript. This work was funded by the Agence Nationale de la Recherche (Laboratoire d’Excellence Revive, Investissement d’Avenir; ANR-10-LABX-73).
|
